Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

CSPC Pharmaceutical Group Ltd (1093)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.48 -0.12    -1.82%
30/04 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  HK1093012172 
  • Volume: 48,358,848
  • Bid/Ask: 6.48 / 6.49
  • Day's Range: 6.48 - 6.66
CSPC Pharma 6.48 -0.12 -1.82%

CSPC Pharmaceutical Group Ltd Company Profile

 
Get an in-depth profile of CSPC Pharmaceutical Group Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

23500

Equity Type

ORD

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company has a strategic partnership with Pfizer Inc. to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People’s Republic of China.

Contact Information

Address No. 226 Huanghe Street
Shijiazhuang, 050035
China
Phone 86 31 1870 37015
Fax 86 31 1870 39608

Top Executives

Name Age Since Title
Chuan Chen 57 2016 Independent Non-Executive Director
Qingxi Wang 55 2018 Executive Director
Hongguang Wang 58 2021 Independent Non-Executive Director
Chun Kwok Au 48 2021 Independent Non-Executive Director
Bo Wang 61 2012 Independent Non-Executive Director
Cheuk Kin Law 59 2021 Independent Non-Executive Director
Hao Jiang 38 2020 Executive Director
Weidong Pan 52 2006 Executive Director
Kin Man Chak 56 2005 Executive Director
Zhenguo Wang 52 2012 Executive Director
Huaiyu Wang 59 2010 Executive Director
Chunlei Li 46 2017 Executive Director & Chief Scientist
Dongchen Cai 68 1997 Executive Chairman
Cuilong Zhang 53 2018 Vice-Chairman & CEO
Quan Li 42 2022 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

1093 Comments

Write your thoughts about CSPC Pharmaceutical Group Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
JAME Megueni
VRAQ Aug 01, 2022 12:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nomura Drops CSPC PHARMA TP to $11.14, Rating Buy
JAME Megueni
VRAQ May 25, 2022 10:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
C Suisse Axes CSPC PHARMA TP to $12, Rating Outperform
JAME Megueni
VRAQ Mar 22, 2022 11:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nomura Raises CSPC PHARMA TP to $12.32, Rated Buy
JAME Megueni
VRAQ Dec 06, 2021 9:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
M Stanley Axes CSPC PHARMA TP to $12, Rated Overweight
JAME Megueni
VRAQ May 25, 2021 10:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Daiwa Downgrades CSPC PHARMA to ***Underperform,*** Lifts TP to $9.9
JAME Megueni
VRAQ May 24, 2021 10:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
C Suisse Ramps up CSPC PHARMA TP to $14; Rated ***Outperform***
JAME Megueni
VRAQ May 23, 2021 10:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
M Stanley Heightens CSPC PHARMA TP to $12.7; Rated ***Overweight***
JAME Megueni
VRAQ Mar 16, 2021 2:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Credit Suisse Lifts CSPC PHARMA  TP to $11.5 as Management Guides For Double-digit FY21 Rev. Growth
JAME Megueni
VRAQ Jan 27, 2021 9:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HSBC Global Research Inches Down CSPC PHARMA (1093) TP to $14.3; ***Rated Buy***
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email